VGX-1027 (GIT 27)

Description: VGX-1027 (also known as GIT 27) is an orally bioactive, isoxazoline compound with potent immunomodulatory properties by inhibiting the toll-like receptor 4 (TLR4) signaling pathway. VGX-1027 significantly inhibits both IL-1beta/IFN-gamma-induced TNF-alpha and nitrite accumulation, and causes a significant increase in cell survival by interfering with the cytotoxic effects of the cytokines. In microarray analysis, VGX-1027 modulated the expression of genes that involved in immune activation and the antigen processing and presentation in response to lipopolysaccharide (LPS) stimulation.

References: J Pharmacol Exp Ther. 2007 Mar; 320(3):1038-49; Eur J Pharmacol. 2008 May 31; 586(1-3):313-21.